Skip to main content
The Journal of Physiology logoLink to The Journal of Physiology
. 2018 Feb 14;596(6):1035–1061. doi: 10.1113/JP275292

Muscle molecular adaptations to endurance exercise training are conditioned by glycogen availability: a proteomics‐based analysis in the McArdle mouse model

Carmen Fiuza‐Luces 1,, Alejandro Santos‐Lozano 2,3, Francisco Llavero 4, Rocío Campo 5, Gisela Nogales‐Gadea 6,7, Jorge Díez‐Bermejo 8, Carlos Baladrón 3, África González‐Murillo 9, Joaquín Arenas 1, Miguel A Martín 7, Antoni L Andreu 7,10, Tomàs Pinós 7,10, Beatriz G Gálvez 2,8, Juan A López 5,11, Jesús Vázquez 5,11, José L Zugaza 4,12,13, Alejandro Lucia 2,8
PMCID: PMC5851888  PMID: 29315579

Abstract

Key points

  • Although they are unable to utilize muscle glycogen, McArdle mice adapt favourably to an individualized moderate‐intensity endurance exercise training regime. Yet, they fail to reach the performance capacity of healthy mice with normal glycogen availability.

  • There is a remarkable difference in the protein networks involved in muscle tissue adaptations to endurance exercise training in mice with and without glycogen availability.

  • Indeed, endurance exercise training promoted the expression of only three proteins common to both McArdle and wild‐type mice: LIMCH1, PARP1 and TIGD4.

  • In turn, trained McArdle mice presented strong expression of mitogen‐activated protein kinase 12 (MAPK12).

Abstract

McArdle's disease is an inborn disorder of skeletal muscle glycogen metabolism that results in blockade of glycogen breakdown due to mutations in the myophosphorylase gene. We recently developed a mouse model carrying the homozygous p.R50X common human mutation (McArdle mouse), facilitating the study of how glycogen availability affects muscle molecular adaptations to endurance exercise training. Using quantitative differential analysis by liquid chromatography with tandem mass spectrometry, we analysed the quadriceps muscle proteome of 16‐week‐old McArdle (n = 5) and wild‐type (WT) (n = 4) mice previously subjected to 8 weeks’ moderate‐intensity treadmill training or to an equivalent control (no training) period. Protein networks enriched within the differentially expressed proteins with training in WT and McArdle mice were assessed by hypergeometric enrichment analysis. Whereas endurance exercise training improved the estimated maximal aerobic capacity of both WT and McArdle mice as compared with controls, it was ∼50% lower than normal in McArdle mice before and after training. We found a remarkable difference in the protein networks involved in muscle tissue adaptations induced by endurance exercise training with and without glycogen availability, and training induced the expression of only three proteins common to McArdle and WT mice: LIM and calponin homology domains‐containing protein 1 (LIMCH1), poly (ADP‐ribose) polymerase 1 (PARP1 – although the training effect was more marked in McArdle mice), and tigger transposable element derived 4 (TIGD4). Trained McArdle mice presented strong expression of mitogen‐activated protein kinase 12 (MAPK12). Through an in‐depth proteomic analysis, we provide mechanistic insight into how glycogen availability affects muscle protein signalling adaptations to endurance exercise training.

Keywords: Glycogenosis type V, McArdle disease, proteome, signalling networks, training, exercise

Key points

  • Although they are unable to utilize muscle glycogen, McArdle mice adapt favourably to an individualized moderate‐intensity endurance exercise training regime. Yet, they fail to reach the performance capacity of healthy mice with normal glycogen availability.

  • There is a remarkable difference in the protein networks involved in muscle tissue adaptations to endurance exercise training in mice with and without glycogen availability.

  • Indeed, endurance exercise training promoted the expression of only three proteins common to both McArdle and wild‐type mice: LIMCH1, PARP1 and TIGD4.

  • In turn, trained McArdle mice presented strong expression of mitogen‐activated protein kinase 12 (MAPK12).

Introduction

The importance of endogenous muscle glycogen as a primary fuel source during exertion (particularly for intense endurance bouts) has been a fundamental concept in exercise physiology for half a century (Bergstrom et al. 1967; Pernow & Saltin, 1971). Accordingly, carbohydrate‐rich diets have been traditionally recommended for athletes to ensure the replenishment of muscle glycogen stores to meet the metabolic demands of intense training exercise sessions and competitions (Bartlett et al. 2015). However, training with low muscle glycogen availability might induce some beneficial metabolic adaptations in the muscle tissue, including activation of key cell signalling kinases (e.g. protein kinase, AMP‐activated, catalytic subunit α 1 and p38 mitogen‐activated protein kinase (p38MAPK)), transcription factors (e.g. protein 53 (p53), peroxisome proliferator‐activated receptor delta (PPARδ)) and transcriptional co‐activators (e.g. peroxisome proliferator‐activated receptor‐1α (PGC‐1α)) (Bartlett et al. 2015), increased fat oxidation (Lane et al. 2015), or delayed liver glycogenolysis (Webster et al. 2016). Elucidating the muscle metabolic adaptations to endurance exercise training as a function of glycogen availability is of interest as it may help to gain insight into the mechanisms that mediate the muscle adaptations to this type of training. This issue can be solved effectively by studying McArdle's disease because it allows the investigation of the effects of total unavailability of muscle glycogen on muscle adaptations to endurance exercise training without the need for dietary (e.g. extreme restrictions in carbohydrate intake) or pharmacological manipulations.

McArdle's disease (glycogen storage disease type V, OMIM® 232600) is the most prevalent disorder of muscle glycogen metabolism. This autosomal recessive disease is caused by pathogenic mutations (the most common of which is the stop codon mutation p.R50X) in both alleles of the PYGM gene (MIM#608455) encoding the skeletal‐muscle isoform of glycogen phosphorylase, ‘myophosphorylase’, which leads to total deficiency of the enzyme (Santalla et al. 2014). Because myophosphorylase catalyses the breakdown of glycogen into glucose 1‐phosphate in skeletal muscle fibres, patients are unable to obtain energy from their muscle glycogen stores (Santalla et al. 2014). This disorder provokes ‘exercise intolerance’ in virtually all affected individuals, which typically manifests in the form of acute crises of undue fatigue and muscle pain and stiffness since childhood (Lucia et al. 2012). Paradoxically, patients who are physically active are less severely affected than their inactive peers (Lucia et al. 2012). Prior non‐controlled studies have reported benefits of supervised, moderate‐intensity ‘aerobic’ exercise interventions (60–70% of maximum heart rate) for patients with McArdle's disease, in the form of increased peak oxygen uptake (V˙O2 peak ) (Haller et al. 2006; Mate‐Munoz et al. 2007) associated with improvements in the muscle levels of two key aerobic enzymes, citrate synthase and β‐hydroxyacyl coenzyme A dehydrogenase (Haller et al. 2006). No other molecular data are, however, available on muscle tissue adaptations to training in these patients.

We recently generated a knock‐in mouse model of McArdle's disease (mice homozygous for the pygm p.R50X mutation; Nogales‐Gadea et al. 2012; Brull et al. 2015). Because this model closely mimics the phenotypes observed in patients (Nogales‐Gadea et al. 2012), it can serve as a useful tool to assess the effects of potential treatment interventions for McArdle's disease, including endurance exercise training. It was therefore the aim of our study to identify key proteins and pathways involved in the endurance exercise training adaptations at the muscle tissue level in McArdle's disease. To do this, we examined, using a controlled design, the effects of submaximal endurance training on the skeletal muscle proteome of wild‐type (wt/wt) and McArdle (p.R50x/p.R50x) mice.

Methods

Ethical approval

The study received ethical institutional (Centre of Energy, Environment and Technical Research, CIEMAT) review board approval (reference number 179/15). Experiments were carried out according to the guidelines laid down by the institution's welfare committee, and conformed to the principles and regulations as described by Grundy (2015). All procedures were carried out according to European and Spanish legislative and regulatory guidelines (European convention ETS 123, on the use and protection of vertebrate mammals in experimentation and for other scientific purposes, and Spanish Law 32/2007, and R.D. 1201/2005 on the protection and use of animals in scientific research). The investigators of the present study understand the ethical principles under which The Journal of Physiology operates and our work complies with its animal ethics checklist. Whenever possible, efforts were made to minimize animal discomfort (see ‘Endurance exercise training intervention in McArdle and wild‐type mice’).

Animals

Founder p.R50X/p.R50X knock‐in mice of mixed genetic background (Nogales‐Gadea et al. 2012) were backcrossed onto the wild‐type CB7Bl/6J background for 10 generations. All the animals were genotyped with LoxP‐F and LoxP‐R as previously reported (Nogales‐Gadea et al. 2012).

A total of 36 male mice (age: 8 weeks; wild‐type: n = 18; McArdle: n = 18) were housed in Eurostandard type IIL microisolator cages (five mice maximum in each) under controlled conditions of temperature and humidity (20 ± 2°C and 55 ± 10%, respectively) at the animal facility of the CIEMAT (registration no. ES280790000183, Madrid, Spain). The cages were lit (fluorescent lighting) from 07.00 to 19.00 h, and food (Harlan Teklad Global Diets 2914) and water (50 μm filtered and UV irradiated) were provided ad libitum.

Study design and endurance exercise training intervention

Pre‐training phase

Mice were allowed to adapt to the treadmill (Harvard Apparatus; Panlab, Barcelona, Spain) in three sessions (on three separate days) as described (Fiuza‐Luces et al. 2013); adaptation involved a gradual increase in running time, treadmill velocity and inclination, starting with placement of the mouse on the treadmill with movement at a very low speed during the first day (0% inclination and 0–5 cm s−1 speed for 1 min, with 0.1 mA electrical stimulation) and ending with a 20 min period at low running intensity on the third day (15% and 12 cm s−1, electrical stimulation 0.1 mA, 1 Hz, 200 ms). A total of four treadmills were used and each mouse was consistently trained and tested on the same treadmill.

Maximal endurance exercise performance test

Once the mice had adapted to the treadmill, they were subjected to a gradual test until exhaustion to determine total running distance as a proxy of their maximal aerobic capacity (Hoydal et al. 2007). The test was performed after a warm‐up period of 20 min at a speed of 12 cm s−1 (with 15% inclination), and followed a previous protocol from our group with slight modifications in workload increases (Fiuza‐Luces et al. 2013). Thus, the initial velocity was 5 cm s−1, and this was followed by workload increases of 3 cm s−1 every 2 min until exhaustion, while treadmill inclination was kept constant at 15% during the whole test and use of electrical stimulation (0.1 mA, 1 Hz, 200 ms). Mice were defined as exhausted when they spent more than 5 s continuously on the electric grid and were unable to continue running at the next speed (Ayala et al. 2009).

Group assignment

McArdle mice were paired‐matched based on the total running distance they reached during the aforementioned test, and each pair was randomly assigned to an exercise (n = 9, subjected to an 8‐week exercise training programme) or a control (‘sedentary’) group (n = 9, allowed to freely move in the cage, but did not perform the programme). The same method of group (exercise or control) assignment and number of animals per group was applied for wild‐type mice.

Endurance exercise training intervention in McArdle and wild‐type mice

Training load over a period of time is the result of the combination of frequency, duration and intensity of the different sessions. Thus, for the training loads of the two McArdle and wild‐type exercise groups during the 8‐week period to be comparable despite their different fitness level at baseline, we ensured that the weekly frequency of training sessions and the duration and relative intensity (the latter expressed as a percentage of the velocity reached at the end of the tests, V max) of each session was the same for the two groups. Thus, the intervention in both exercise groups included five weekly sessions (from Monday to Friday; session duration, 30–50 min), which was performed between 08.00 and 12.00 h. The duration and relative intensity of each session were also the same and increased gradually in the same manner in the two groups, beginning at low workloads in the first session (30 min at 50% of V max and 0% gradient on the first day) and ending with 50 min at 70–75% of V max and 15% gradient at the end of the programme (Fiuza‐Luces et al. 2013). All the sessions included a warm‐up period (15 min at 40% (start of the programme) to 50% of V max (end)) and were followed by a cool‐down period (5 min at 35% of V max), both at the same treadmill slope used for the core part.

Whenever possible, efforts were made to minimize animal discomfort. Thus, only gentle tail touching was used to prompt the mice to run and no electrical stimulation was applied during the training sessions. In addition, because carbohydrate ingestion 30–40 min prior to exercise attenuates the risk of muscle damage in McArdle's disease (Lucia et al. 2008), for ethical reasons, during the hour before each session the McArdle mice were fed one Fruit CrunchiesTM pellet (weight, 190 mg; 52% energy from carbohydrate, 20.2% protein, 11.5% fibre, 6.3% fat, 5.1% ash and <10% moisture) (Bio‐ServTM, LBS Serving Biotechnology, UK). We verified that all exercise sessions started after the mice had eaten the pellet (which consistently took ≤60 min). Ingestion of pellets was chosen instead of parenteral administration of glucose to minimize animal discomfort. To ensure similar conditions in all groups, all the study mice also consumed the aforementioned pellet at the same time of the day.

Post‐training phase

At the end of the endurance exercise training programme, all animals repeated the aforementioned performance test. Finally, 48 h after the last test, mice were killed by intraperitoneal injection with a lethal dose of Avertin (0.2%, 0.15 ml g−1). We dissected the quadriceps muscles, trimmed of connective tissue, which were immediately snap‐frozen in liquid nitrogen before storage at −80°C for proteomics analysis. We chose the quadriceps instead of other limb muscles (tibialis anterior, extensor digitorum longus, or soleus) based on its high glycolytic phenotype, for technical reasons (i.e. large size, allowing sufficient amount of sample for present and future investigations), and also for its use in recent research from our group aiming at identifying molecular markers of important cell functions (energy‐sensing pathways, oxidative phosphorylation and autophagy/proteasome systems, oxidative damage, and sarcoplasmic reticulum Ca2+ handling) in McArdle mice (Fiuza‐Luces et al. 2016).

Paired comparisons were made between the maximal distance measured before and after the training period in the exercise and control group, in both McArdle and wild‐type mice (Wilcoxon test). Analyses were performed with Stata statistical software (version 13, Stata Corp; College Station, TX, USA) for Mac. The statistical significance level was set at P < 0.05.

Proteomic analysis

Proteomic analysis was performed in 10 McArdle (5 per group) and 8 wild‐type (4 per group) mice.

Sample preparation

Muscle samples were extracted in lysis buffer (2% SDS, 10 mm Tris(2‐carboxyethyl) phosphine hydrochloride (TCEP) and 50 mm Tris–HCl, pH 7.5) by homogenizing the tissue with 3 cycles at 6500 rpm for 60 s each using a MagNA Lyser Instrument (Roche; Mannheim, Germany). Thereafter, samples were boiled for 5 min and incubated for 30 min at room temperature with agitation. Samples were centrifuged at 16,000 g for15 min, and protein concentration in the supernatant was determined with a Direct Detect IR spectrometer (Millipore Ibérica; Madrid, Spain).

Protein digestion and isobaric labelling

For the quantitative differential analysis by liquid chromatography with tandem mass spectrometry (LC‐MS/MS) using isobaric tags (TMT 10‐plex), ∼100 μg of total proteins was digested using the filter‐aided protocol as previously described with minor modifications (Cardona et al. 2015). Proteins were diluted in 7 m urea and 0.1 mm Tris–HCl (pH 8.5) (UA) and loaded onto 10 kDa centrifugal filter devices (NanoSep 10k Omega, Pall Life Sciences; Port Washington, NY, USA). The buffer was replaced by washing filters with UA, and proteins were then alkylated using 50 mm iodoacetamide (IAA) in UA for 30 min in the dark. The excess of alkylating reagent was eliminated by washing three times with UA and three additional times with 50 mm ammonium bicarbonate. Proteins were digested overnight at 37°C with modified trypsin (Promega Biotech Ibérica; Alcobendas, Madrid, Spain) in 50 mm ammonium bicarbonate at 30:1 protein:trypsin (w/w) ratio. The resulting peptides were eluted by centrifugation with 50 mm ammonium bicarbonate (twice) and 0.5 m sodium chloride. Trifluoroacetic acid (TFA) was added to a final concentration of 1% and the peptides were desalted onto C18 Oasis‐HLB cartridges (Waters; Milford, MA, USA) and dried‐down for further analysis.

For stable isobaric labelling, the resulting tryptic peptides were dissolved in 100 mm tri‐ethyl‐ammonium bicarbonate (TEAB) buffer, and the peptide concentration was determined by measuring amide bonds with the Direct Detect system (Millipore Ibérica). Equal amounts of each peptide sample were labelled using 10‐plex TMT Reagents (Thermo Fisher Scientific; Waltham, MA) according to the manufacturer's protocol. Peptides were labelled with TMT reagents previously reconstituted with 70 μl of acetonitrile; after incubation at room temperature for 2 h, the reaction was stopped with 0.5% TFA, incubated for 30 min, and peptides were combined. Samples were concentrated in a Speed Vac, desalted onto C18 Oasis‐HLB cartridges and dried‐down for further analysis. To increase proteome coverage, TMT‐labelled samples were fractionated by high‐pH reverse phase chromatography (High pH Reversed‐Phase Peptide Fractionation Kit, Pierce; Rockford, IL, USA) and concentrated as before.

Protein identification and quantification

Labelled peptides were analysed by LC‐MS/MS using a C‐18 reversed phase nano‐column (75 μm I.D. × 50 cm, 2 μm particle size, Acclaim PepMap RSLC 100 C18; Thermo Fisher Scientific, Waltham, MA, USA) in a continuous acetonitrile gradient consisting of 0–30% B in 360 min and 50–90% B in 3 min (A = 0.1% formic acid; B = 90% acetonitrile, 0.1% formic acid). A flow rate of 200 nl min−1 was used to elute peptides from the nano‐column to an emitter nanospray needle for real time ionization and peptide fragmentation on an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific). An enhanced FT‐resolution spectrum (resolution = 70,000) followed by the MS/MS spectra from the Nth most intense parent ions were analysed along the chromatographic run. Dynamic exclusion was set at 40 s.

For peptide identification, all spectra were analysed with Proteome Discoverer (version 2.1.0.81, Thermo Fisher Scientific) using SEQUEST‐HT (Thermo Fisher Scientific). For database searching at the Uniprot database containing all sequences from mouse and contaminants (27April 2016; 48,644 entries), the parameters were selected as follows: trypsin digestion with two maximum missed cleavage sites, precursor and fragment mass tolerances of 2 Da and 0.02 Da, respectively, carbamidomethyl cysteine and TMT modifications at N‐terminal and Lys residues as fixed modifications, and methionine oxidation as dynamic modification. Peptide identification was performed using the probability ratio method (Martinez‐Bartolome et al. 2008) and false discovery rate (FDR) was calculated using inverted databases and the refined method (Navarro & Vazquez, 2009) with an additional filtering for precursor mass tolerance of 15 ppm (Bonzon‐Kulichenko et al. 2015).

Identified peptides with an FDR equal to or lower than 1% FDR were used to quantify the relative abundance of each protein from reporter ion intensities, and statistical analysis of quantitative data was performed using the WSPP statistical model previously described (Navarro et al. 2014). In this model, protein log2‐ratios are expressed as standardized variables; that is, in units of standard deviation (SD) according to their estimated variances (Z q values).

Functional protein analysis

Functional protein analysis of the whole set of quantified proteins was performed using a novel algorithm system biology triangle (SBT), developed specifically for the analysis of coordinated protein responses in high‐throughput quantitative proteomics experiments (Garcia‐Marques et al. 2016). This algorithm correlates the performance of a group of proteins inside a category (biological process) in terms of their quantitative behaviour (relative abundance); thus, changes can be detected in functional biological processes far beyond individual protein responses. Variations in the abundance of annotated functional categories were visualized by comparing the cumulative frequency (sigmoid) plots of the standardized variable with that of the normal distribution, as in previous research (Isern et al. 2013). Individual protein changes were also considered for further analysis.

Determination of the differentially expressed proteins

The Kolmogorov–Smirnov test was applied to test if the data followed a normal distribution. Student's t test or the Wilcoxon rank‐sum test was applied to identify differentially expressed proteins (i.e. ‘proteins of interest’) between exercise and control groups in both McArdle and wild‐type mice. P‐values were adjusted for multiple comparisons with FDR correction.

Biocomputational analysis of proteomics data

Processing of protein expression data

Murine proteins were converted into the corresponding human equivalent UniProt reviewed protein according to the following steps: (i) UniProt ID automatic crossing of the murine proteins with human proteome with corresponding databases (InParanoid (Sonnhammer & Ostlund, 2015) and the Mouse Genome Database (MGD; Blake et al. 2017)), (ii) gene name automatic crossing of the murine proteins with human proteome with corresponding databases (InParanoid; Turk et al. 1990) and (iii) Manual Blast (Altschul et al. 1990), selecting the best reviewed match presenting at least an identity value ≥ 70% and E‐value ≤ 10−6.

Molecular characterization of adaptation to endurance exercise training

Adaptation to endurance exercise training was characterized at the molecular level via manual curation of the literature. This characterization was performed in two steps: in the first step, we identified the main pathophysiological processes related to ‘manifestative’ adaptations in the skeletal muscle in response to endurance exercise training (‘manifestative’ signatures), which were further characterized at the protein level to provide a final list of ‘condition effector’ proteins (hereafter termed ‘effectors’) (Appendix, Table A1). Hence, effectors are those proteins that, according to the existing literature, have previously been reported to play a critical role in the process of interest for a given study viz., skeletal muscle adaptations to endurance exercise training (databases: PubMed, ScienceDirect and Scopus; key words (and combinations thereof): protein, muscle, physical adaptations, sports, exercise, McArdle's disease and McArdle).

Contextualization of the differentially expressed proteins within ‘adaptation to exercise training’ protein network

Effector proteins were used to focus the analysis on the biological condition of interest in the human biological network. The direct interactions (physical interactions or functional relationships) among the differentially expressed proteins (in exercise vs. control groups), as well as the interactions between the differentially expressed proteins and the effectors of skeletal muscle adaptations to endurance exercise training, were assessed. Different publicly available databases were consulted for the human protein network generation (e.g. Reactome, Molecular INTeraction database (MINT) and BioGrid) (Herrando‐Grabulosa et al. 2016; Iborra‐Egea et al. 2017).

Mechanistic evaluation of the differentially expressed proteins in relation to endurance exercise training: artificial neuronal networks analysis

The possible molecular relationship between the differentially expressed proteins and skeletal muscle adaptations to endurance exercise training was evaluated by means of artificial neuronal networks (ANNs), following TPMS technology protocols (Herrando‐Grabulosa et al. 2016; Iborra‐Egea et al. 2017). This approach involves the generation of mathematical models of the biological processes through the use of artificial intelligence techniques. Then, mathematical models were solved by ANNs, which are supervised algorithms that identify relationships between the different nodes in the network. ANN analysis yields a score for each differential protein based on the validations of the prediction capacity of the mathematical models towards known drugs and diseases, as described in databases. The higher the score, the stronger is the predicted mechanistic relationship between the evaluated protein and the biological process. Each score is associated with a P‐value that describes the probability of the result being a true positive one. Aiming to facilitate the understanding of the results, the obtained scores were divided into three categories: >76, strong (P < 0.05); 40–76, medium‐strong (P = 0.05–0.25); and <40, weak (P > 0.25).

Proteins presenting 200+ interactions (‘sticky proteins’), or proteins that do not have reported interactions, were not included in the topology as they may disrupt the correct assessment of existing relationships (Pache et al. 2008). Relationships between the differentially expressed proteins and skeletal muscle adaptations to endurance exercise training were assessed both for individual proteins and for combinations of two proteins; thus, from all the reported protein interactions, the most interesting are those presenting a synergic effect. The synergy criteria were applied according to the approach described by Berenbaum (1989), in which a significant synergic effect is considered when the overall effect is >20% of the sum of the individual effects of the two proteins.

Visualization of the protein network

Cytoscape 3.5.1. software was used to study the representation of all the reported interactions (both from the significantly associated proteins and non‐significantly associated proteins) according to the ANN score.

Enrichment analysis

The pathways and biological processes enriched within the differentially expressed proteins in the exercise and control groups within both McArdle and wild‐type mice were assessed using a hypergeometric enrichment analysis approach (Rivals et al. 2007). Specifically, the enrichment was run over several sets of proteins, including: Gene Ontology (GO) terms (Biological Process, Cellular Component, Molecular Function) according to European Molecular Biology Laboratory (EMBL)–European Bioinformatics Institute (EBI)/UniProt‐GO (The UniProt Consortium, 2017); pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG; Kanehisa et al. 2014), the Pharmacogenomics Knowledgebase (PharmGKB; Whirl‐Carrillo et al. 2012) and the Small Molecule Pathway Database (SMPDB; Frolkis et al. 2010); pathological conditions, signatures and pathways from the Biological Effectors Database (BED; Iborra‐Egea et al. 2017) and the regulatory molecular mechanisms included in Transcriptional Regulatory Relationships Unraveled by Sentence‐based Text‐mining (TRRUST) database (Han et al. 2015). Only those pathways that showed a statistically significant presence were presented (FDR P‐value < 0.05).

Results

The training loads were common to both McArdle and wild‐type exercise groups over the 8‐week period and are shown in detail in Appendix, Table A2. The endurance exercise training programme was successful in inducing a significant improvement in the total running distance of both McArdle (141 (31 SD) m (pre‐training) vs. 167 (48 SD) m (post‐training); Wilcoxon test P = 0.035) and wild‐type (275 (30 SD) vs. 353 (146 SD) m, P = 0.041) mice, whereas no significant change was found during the same time period in their sedentary controls (140 (41 SD) vs. 116 (48 SD) m, P = 0.129 for McArdle and 302 (85 SD) vs. 296 (103 SD) m, P = 0.726 for wild‐type mice). Although the relative improvement in total running distance did not differ between McArdle and wild‐type mice (Mann–Whitney test, P = 0.111), the total running distance of McArdle mice was ∼50% lower than that of wild‐type mice both before and after the endurance exercise intervention. Individual data (total running distance) of the mice used for proteomic analyses are shown in Fig. 1. When expressed as V max, the test results were as follows: McArdle, exercise group: 26 (3) cm s−1 (pre‐training) vs. 29 (4) cm s−1 (post‐training), Wilcoxon test P = 0.054; wild‐type, exercise group: 36 (6) (pre‐training) vs. 41 (8) cm s−1 (post‐training), P = 0.028; McArdle, sedentary control group: 26 (4) vs. 24 (5) cm s−1, P = 0.123; wild‐type, sedentary control group: 38 (5) vs. 37 (7) cm s−1, P = 0.180.

Figure 1. Individual responses during the intervention period in maximal distance during a gradual treadmill running test until exhaustion in mice used for proteomic analysis.

Figure 1

 

The body mass of the mice showed an increasing trend over time irrespective of genotype or intervention (exercise or control): (i) McArdle, exercise group: 20.8 (1.4) g (pre) and 22.0 (1.3) g (post), Wilcoxon test P = 0.997; (ii) McArdle, control group: 20.8 (1.3) g (pre) and 22.1 (0.81) g (post), P = 0.031; wild‐type, exercise group: 18.7 (2.0) g (pre) and 21.3 (1.0) g (post), P = 0.083; wild‐type, control group: 19.0 (1.9) g (pre) and 21.7 (2.1) g (post), P = 0.805.

Proteomics

Proteins of interest

Data provided by whole proteomic analysis regarding differential proteins within the sedentary and the trained groups of McArdle and wild‐type mice, respectively, were analysed by applying Student's t test and the Wilcoxon rank‐sum test. A total of 74 differentially expressed proteins between the trained and sedentary wild‐type mice and 123 differentially expressed proteins between the trained and sedentary McArdle mice were found (Appendix, Table A3). Of these differentially expressed proteins in response to endurance exercise training, only three were common to wild‐type and McArdle mice: LIM and calponin homology domains‐containing protein 1 (LIMCH1); poly (ADP‐ribose) polymerase 1 (PARP‐1, also known as NAD+ ADP‐ribosyltransferase 1 or poly (ADP‐ribose) synthase 1); and tigger transposable element derived 4 (TIGD4). Expression of all three proteins was higher in endurance exercise training than in untrained conditions, in both wild‐type and McArdle mice; however, statistical significance was not reached for any after FDR adjustment.

Contextualization of the differentially expressed proteins within exercise training adaptation

The molecular characterization of the skeletal muscle adaptations to endurance exercise training was carried out through the review of specialized scientific literature. A total of 76 effector proteins were identified and classified into four groups according to their cellular function, such as adaptive muscle growth (14 proteins), muscle angiogenesis (8 proteins), glucose and lipid metabolism (12 proteins) and mitochondrial biogenesis and remodelling (48 proteins), with four of these 76 proteins belonging to two groups (angiogenesis + mitochondrial biogenesis and remodelling) at the same time, namely cyclic AMP‐dependent transcription factor (ATF2), steroid hormone receptor ERR1 (ESRRA, or also ERRa), mitogen‐activated protein kinase 12 (MAPK12) and myocyte‐specific enhancer factor 2A (MEF2A, or MEF2), and one, PGC‐1α, belonging to three groups (adaptive muscle growth + angiogenesis + mitochondrial biogenesis and remodelling) (Appendix, Table A1).

The role of the differentially expressed proteins in adaptation to endurance exercise training was evaluated according to the molecular characterization performed. The results of the analysis revealed that only one of the differentially expressed proteins in McArdle mice, MAPK12, had been previously related to skeletal muscle adaptations to exercise training (Table 1). MAPK12 is involved both in mitochondrial biogenesis and remodelling and muscle angiogenesis. By contrast, none of the differentially expressed proteins in wild‐type mice has previously been reported to play a direct role in skeletal muscle adaptations to endurance exercise training (Table 2). However, while only one differentially expressed protein from the two lists (McArdle and wild‐type mice) matches the effector proteins defined in the molecular characterization, it is remarkable that several of them interact with many effectors (Tables 1 and 2). In McArdle mice, ATP synthase H+ transporting mitochondrial F1 complex γ polypeptide 1 (ATP5C1), MAPK12 and ATP synthase and H+ transporting mitochondrial F1 complex ε subunit (ATP5E) were related to more than 10 effectors, and proteasome 26S subunit, non‐ATPase 14 (PSMD14), integrin‐linked kinase (ILK) and chaperonin containing TCP1 subunit 3 (CCT3) interacted with nine different effectors, while in wild‐type mice, we found that poly(A) binding protein cytoplasmic 1 (PABPC1), protein kinase DNA‐activated catalytic polypeptide (PRKDC), ribosomal protein lateral stalk subunit P0 (RPLP0), mitogen‐activated protein kinase kinase 4 (MAP2K4) and protein kinase N1 (PKN1) interacted with more than 10 effectors, followed by ribosomal protein L21 (RLP21) interacting with up to nine different effectors. Additionally, the common differentially expressed protein between the two groups, PARP1, interacted with seven different effectors, all of them involved in mitochondrial biogenesis and remodelling.

Table 1.

McArdle (p.R50X/p.R50X) mice: Summary of the interactions found between the differentially expressed proteins (in exercise vs. control groups) and of the protein effectors of skeletal muscle adaptations to endurance exercise training

graphic file with name TJP-596-1035-g008.jpg
graphic file with name TJP-596-1035-g009.jpg

Symbols: non‐effectors (×) and effectors (✓) of skeletal muscle adaptations to endurance exercise training among the differentially expressed proteins.

Table 2.

Wild‐type (wt/wt) mice: summary of the interactions found between the differentially expressed proteins (in exercise vs. control groups) and of the protein effectors of skeletal muscle adaptations to endurance exercise training

graphic file with name TJP-596-1035-g010.jpg

Symbol: ×, non‐effectors of skeletal muscle adaptations to exercise training among the differentially expressed proteins.

Mechanistic evaluation of the relationship with endurance exercise training: analysis of artificial neuronal networks

The potential molecular relationships between the differentially expressed proteins and skeletal muscle adaptations to endurance exercise training were evaluated through the analysis of mathematical models, to determine the possible activity relationships between protein sets or regions inside the network (i.e. ANN); this allowed us to provide a predictive score that quantifies the probability of the existence of a relationship between the evaluated differential proteins and network region (i.e. the different pathophysiological signatures characterized and adaptation to endurance exercise training as a whole). Each score is associated with a P‐value that describes the probability of the result being a true positive result. To better understand the results, we divided the ranking score into four categories: strong (P < 0.05), medium‐strong (P 0.05–0.25), weak (P < 0.25) and not assessed. As shown in Appendix, Table A4, it was not possible to evaluate 5 of 116 proteins for the McArdle mouse groups, and 5 of 73 for the wild‐type groups. Nevertheless, the possible relationship between 111 proteins for McArdle mice and 68 proteins for wild‐type mice was successfully assessed. When considering the differential proteins individually, ∼28% and 22% of the proteins showed a significant relationship (strong or medium‐strong category) with skeletal muscle adaptations to endurance exercise training in McArdle and wild‐type mice, respectively. Moreover, when analysing the differential proteins in sets of two proteins, ∼30% of the protein combinations showed a significant association with skeletal muscle adaptations to endurance exercise training, both in the McArdle and wild‐type mice.

Relationships between the differentially expressed proteins and skeletal muscle adaptations to endurance exercise training: individual protein evaluation

As a result of the analysis of the relationship between individual proteins and skeletal muscle adaptations to endurance exercise training, a total of 33 proteins were reported to present a significant relationship with McArdle's disease mice and 16 with wild‐type mice (Table 3). One of the differentially expressed proteins common to both mouse groups, PARP1, appeared to be significantly related to skeletal muscle adaptations to endurance exercise training. Moreover, the assessment of the potential relationship between the proteins of interest and skeletal muscle adaptations to endurance exercise training signatures allowed the evaluation of specific subsets of the physiological processes that in some cases were not detected by considering the whole context. For instance, nine proteins of interest in McArdle mice and five in wild‐type mice that were predicted to be related to at least one of the signatures of skeletal muscle adaptations to endurance exercise training were actually not found to be related to the general characterization of skeletal muscle adaptations to endurance exercise training (Table 3).

Table 3.

Differentially expressed proteins significantly linked to skeletal muscle adaptations in McArdle and wild‐type mice

graphic file with name TJP-596-1035-g011.jpg
graphic file with name TJP-596-1035-g012.jpg

The higher the artificial neuronal network (ANN) predictive score, the stronger is the relationship between the protein and skeletal muscle adaptations to endurance exercise training or its motives. Inline graphic ANN score (strong relationship) > 76% P‐value < 0.05 Inline graphic ANN score 40–76 (strong‐medium) P‐value 0.05‐0.25 Inline graphic ANN score (weak) < 40% P‐value < 0.25.

Relationships between the differentially expressed proteins and skeletal muscle adaptations to endurance exercise training: association in combination of two proteins

As a result of the analysis of the relationship between combinations of two proteins and skeletal muscle adaptations to endurance exercise training (Appendix, Table A4), a total of 2035 protein combinations were reported to present a significant relationship in McArdle mice and 719 in wild‐type mice. When considering only the combinations with a significant synergic effect (synergic effect is considered when the overall effect is >20% of the amount of the individual effect of the two proteins), a total of 199 and 57 protein combinations were found for McArdle and wild‐type mice, respectively. One of the common differentially expressed proteins in both groups, LIMCH1, appeared to be significantly related to skeletal muscle adaptations to endurance exercise training in combination with other proteins.

In order to represent the intermolecular relationships obtained regarding protein interactions (Tables 1 and 2 and Appendix, Table A1) and mechanistic evaluation (Appendix, Table A4), a visual protein interaction network map was generated for both McArdle (Fig. 2) and wild‐type (Fig. 3) mice. Only the proteins with a significant relationship with skeletal muscle adaptations to endurance exercise training (based on ANNs score) and their direct interactions appear on the representations. However, closer analysis of the signalling networks revealed that PARP1 was more profoundly overexpressed in trained McArdle than in trained wild‐type mice (Figs 2 and 3, respectively).

Figure 2. Visual protein interaction network of the proteins significantly related to skeletal muscle adaptations to endurance exercise training according to the artificial neuronal network score (ANNs), and their interacting proteins, in McArdle (p.R50X/p.R50X) mice.

Figure 2

The network includes three representations of the following interactions: (i) within the differentially expressed proteins (ovals), (ii) between the differentially expressed proteins and skeletal muscle adaptions to endurance exercise effectors (ovals and triangles), and (iii) within the skeletal muscle adaptations to endurance exercise effectors (triangles). Note: all the interactions, from both the significantly associated proteins and the non‐significantly associated proteins according to the ANN score, are reported.

Figure 3. Visual protein interaction network of the proteins significantly related to skeletal muscle adaptations to endurance exercise training according to the artificial neuronal network score (ANNs), and their interacting proteins, in wild‐type (wt/wt) mice.

Figure 3

The network includes include three representations of the following interactions: (i) within the differentially expressed proteins (ovals), (ii) between the differentially expressed proteins and skeletal muscle adaptions to endurance exercise effectors (ovals and triangles), and (iii) within the skeletal muscle adaptations to endurance exercise effectors (triangles).

Enrichment analysis

To analyse the expression data related to signalling pathways and clinical conditions, we undertook a hypergeometric enrichment analysis approach within the differentially expressed proteins in the trained and the control groups of McArdle and wild‐type mice. As shown in Appendix, Table A5, 121 and 79 protein sets were found enriched in the comparison of control vs. exercise groups, both in McArdle and in wild‐type mice. Subsequently, a pathway comparison between the results obtained from both conditions was performed, obtaining four common pathways and 117 and 75 proteins specifically enriched in McArdle and wild‐type groups, respectively. The enriched protein sets common to McArdle and wild‐type conditions corresponded to those related to high blood glucose levels and gene expression (BEDVES database: induction of oxidative stress diabetic neuropathies and induction of oxidative stress diabetic neuropathies and retinopathies; GOFUNTION database: term poly(A) RNA binding and the GOLOCATION referring to cytosol).

The enriched protein sets reported within the differentially expressed proteins in exercise vs. control McArdle mice (Appendix, Table A5) reflect changes related to muscular adaptations to endurance exercise training that may be related to improvement in exercise tolerance, as well as to processes associated with the pathophysiology of the condition. Regarding enriched protein sets related to muscular adaptations to endurance exercise training, there were several pathways referring to mitochondria and their functions (Appendix, Table A6), including GO location terms referring to several mitochondrial structures such as the proton‐transporting ATP synthase complex (responsible for ATP synthesis), and GO processes such as the respiratory electron transport chain. Furthermore, several pathways and GO terms related to lipid and protein metabolism are also reported in Appendix, Table A6, and enriched protein sets related to muscle structure and growth are described in Appendix, Table A7.

Conversely, the enriched protein sets within the wild‐type groups were mainly related to endurance exercise training‐induced physiological changes due to focal adhesion, actin cytoskeleton reorganization and phosphatidylinositol 3‐kinase (PI3K) signalling pathway involvement (Appendix, Table A8). Moreover, several pathways referring to β‐blocker activity also appeared to be enriched, possibly due to changes in catecholamine modulation (Appendix, Table A9).

Discussion

Although McArdle's disease causes ‘exercise intolerance’ (Lucia et al. 2012), under carefully controlled conditions, McArdle's patients may perform acute exercise safely, especially if carbohydrate solutions are taken before exercise to bypass the metabolic blockade that occurs upstream of the uptake of glucose by muscle fibres (Vissing & Haller, 2003). They may also adapt favourably to moderate‐intensity endurance exercise training (Haller et al. 2006; Mate‐Munoz et al. 2007). Yet, no study has assessed in depth the molecular signals associated with muscle exercise adaptations in McArdle's patients and how they compare with those of healthy individuals. Accordingly, in the present study we aimed to identify, with no a priori hypothesis, the key proteins and protein networks linked to the effects of moderate‐intensity endurance exercise training in a mouse model that closely mimics the phenotype of McArdle's patients (Nogales‐Gadea et al. 2012). Unravelling the muscle metabolic adaptations to endurance exercise training with no muscle glycogen availability might help to gain insight into the proteome profile that characterizes muscle adaptations to such a type of training. This is an important question given that the skeletal muscle contains 50–75% of all the body proteins and is responsible for 30–50% of the whole body protein translation process (Frontera & Ochala, 2015). The majority of proteins identified here both in McArdle and wild‐type mice control the expression of myriad genes related to angiogenesis, carbohydrate, lipid and protein metabolism, mitochondrial biogenesis and remodelling, and muscle growth.

In addition to reporting the first non‐pharmacological intervention in this mouse model, a novel finding of our study was that, like patients, McArdle mice adapt favourably to an individualized moderate‐intensity endurance exercise training regimen (albeit without reaching the performance capacity of healthy mice). Yet, our results revealed a remarkable difference in the protein networks involved in the muscle tissue adaptations that occur with endurance exercise training with normal glycogen availability (wild‐type mice) as compared with those that occur in conditions of blocked glycogenolysis (McArdle mice). Indeed, endurance exercise training promoted the expression of only three proteins common to both McArdle and wild‐type mice: LIMCH1, PARP1 and TIGD4. Likely, all three proteins play a prominent role in the relationship between skeletal muscle plasticity and endurance exercise training, independent of muscle glycogen availability, which warrants further investigation. It is well known that during exercise, numerous stress signals are transduced to activate intracellular signalling pathways controlling skeletal muscle gene transcription and translation (Bassel‐Duby & Olson, 2006; Koulmann & Bigard, 2006; Favier et al. 2008; Russell, 2010). Against this background, both LIMCH1 and PARP1 could participate in stress pathways controlled by exercise. Indeed, cell contraction accelerates when LIMCH1 promotes the assembly of actin stress fibres during cell spreading. Moreover, the absence of LIMCH1 expression impacts the formation of actin stress fibres as well as the stability of focal adhesions (Lin et al. 2017), which are fundamental structures in the union of muscle fibres to ensure optimal contraction and muscular distention. TIGD4 protein belongs to the tigger subfamily of the pogo superfamily of DNA‐mediated transposons in humans. The latter proteins are related to DNA transposons found in fungi and nematodes and more distantly to transposases Tc1 and mariner, and they are very similar to the major mammalian B centromere protein. However, the exact function of TIGD4 remains to be clarified.

PARP1 is the most characterized member of the PARP family of nuclear enzymes. These proteins are sensitive to changes in intracellular redox pathways, positioning the poly ADP‐ribosylation (PARylation) reaction as an important biochemical marker of oxidative stress (Jungmichel et al. 2013). Whereas basal activity of PARP1 is crucial to maintain cellular homeostasis, its over‐activity leads to an increase in protein PARylation, which in turn depletes intracellular NAD+ levels, leading to cell death (Ha & Snyder, 1999). Thus, PARP1 activity is a key sensor for cell survival. Interestingly, we found that endurance exercise training mediates the expression of PARP1 in both McArdle and wild‐type mice, although it was higher in trained McArdle than in trained wild‐type mice. This could be due, at least partly, to high muscle damage that characterizes this disease.

In general, the low overlap between groups (74 and 123 differentially expressed proteins with training in wild‐type and McArdle mice, respectively) suggests considerable differences in the physiological adaptations to chronic endurance exercise between McArdle and wild‐type mice, at a mechanistic level. Indeed, when we compared the protein profile between McArdle and wild‐type mice after training, we found that McArdle mice presented a specific and strong expression of MAPK12 and a potentially substantial number of effector interactions. MAPK12 is a serine/threonine kinase that acts as an essential component of the MAP kinase signal transduction pathway. Also known as p38MAPKγ, MAPK12 is one of the four p38 MAPKs that play an important role in the cellular response cascade induced by extracellular stimuli such as proinflammatory cytokines or physical stress (Cuenda & Rousseau, 2007). MAPK12 plays a role in myoblast differentiation, as it is involved in the regulation of the expression of the solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1). Further, basal glucose uptake in L6 myotubes and MAPK12 signalling positively regulate the expansion of transient amplifying myogenic precursor cells during muscle growth and regeneration (Ho et al. 2004). Our analyses suggest that MAPK12 is also related to mitochondrial biogenesis and remodelling, with such potentially MAPK12‐mediated improvement in mitochondrial function perhaps endeavouring to compensate for the deficit in energy supply owing to glycogen unavailability. By contrast, we detected a lower endurance exercise training‐induced increase in MPAK12 protein expression in wild‐type mice.

Pathway enrichment analysis of the highly and significantly expressed proteins in McArdle and wild‐type mice (121 and 79 proteins, respectively) provided an enrichment in clinical processes that are related to the induction of oxidative stress, neuropathies and retinopathies. When McArdle and wild‐type mice were analysed separately, we observed that after endurance exercise training in McArdle mice the most widely represented functions were those involved in ATP synthesis and electron transport chain processes, β‐oxidation of lipids, and different steps in lipid and protein catabolism. In addition, cell death and regulation of necrotic processes were also reflected in this analysis. In fact, the overexpression of PARP1 could be associated with rhabdomyolysis, and PARP activation is linked to necrosis, as shown in PARP‐deficient mouse fibroblasts (Ha & Snyder, 1999). All of the aforementioned adaptations found in McArdle mice after endurance exercise training may be related to the metabolic strategies that the skeletal muscle tissue of McArdle mice deploys to obtain energy. Conversely, after endurance exercise training the functions that were most represented in wild‐type mice were those related to cytoskeleton regulation and focal adhesions, and also PI3K and mTOR signalling pathway activation related to maintenance of skeletal muscle cell survival. Thus, from an overall perspective, it seems that the main muscle molecular adaptations to endurance exercise training in McArdle mice are more oriented to obtain energy for tissue regeneration in a state of energetic deficit, whereas wild‐type muscle adaptations seem to be more related to support tissue maintenance while coping with exercise stress stimuli.

Our study is not without limitations. In contrast to human research, where performing repeated muscle biopsy sampling may be feasible, a first technical limitation is the impossibility to determine muscle glycogen content before and after a training session in the wild‐type mice as a proof‐of‐concept for glycogen utilization. Of note, owing to the total inability to utilize glycogen as a fuel, massive muscle glycogen accumulation occurs in McArdle mice, a phenomenon much more remarkable than in patients, with muscle glycogen levels being several orders of magnitude higher than in CB7Bl/6J wild‐type mice as used here (Nogales‐Gadea et al. 2012). Moreover, we chose forced treadmill running rather than wheel running as a model of endurance exercise training. Although wheel running is a less stressful, more natural form of activity in rodents, it does not allow for the establishment of predetermined training loads, which was a crucial aspect of our design to ensure they were similar in the exercise groups. Nevertheless, researchers in charge of mouse training were well experienced in mouse handling such as to minimize stress in these animals. Indeed, only gentle tail touching was used to prompt the mice to run and no electrical stimulation was applied during the training sessions. Another potential limitation comes from the use of a single muscle type, quadriceps (with a highly glycolytic phenotype) for proteome analyses. Future research should determine whether comparable findings are obtained in a more oxidative muscle like the soleus or even in other glycolytic muscles. In this regard, although there are differences between muscles (even between those with a similar metabolic phenotype and with only subtle differences in proportion of fibre types, such as the quadriceps and tibialis anterior) overall, both fast‐ and slow‐twitch muscles in the untrained state are affected by both structural degeneration and energy deficiency in McArdle mice (Krag et al. 2016a). Along this line, recent research has identified the quadriceps muscle as having more compensatory adaptations to counterbalance energetic deficiency in the untrained state (i.e. in terms of expression of proteins involved in glucose uptake, glycogen synthesis and glycolysis) than other studied muscles, whether they were predominantly glycolytic (tibialis anterior, extensor digitorum longus) or more oxidative (soleus) (Krag et al. 2016b). Finally, we did not report blood serum creatine kinase levels (as an indirect marker of muscle damage) over the study period.

In conclusion, we have determined that, akin to patients, McArdle mice responded favourably to moderate‐intensity endurance exercise training, although their maximal aerobic capacity is clearly lower than that of normal peers. This suggests that glycogen availability is crucial for ensuring maximal endurance performance in mammals, with unavailability of this substrate resulting in muscles adopting a remarkably different ‘molecular strategy’ to cope with the training loads while ensuring cellular homeostasis during a state of energetic deficit. In this regard, we have identified for the first time the signalling strategies (in terms of signalling molecules and protein networks) that skeletal muscle employs to overcome blockade of glycogen breakdown during endurance exercise training, demonstrating that the protein network involved in muscle adaptations to such a type of training greatly differs depending on glycogen availability (see also Fig. 4 for a summary). Our findings provide a framework for future studies aimed at elucidating the molecular mechanisms associated with the most relevant identified proteins here. It would also be interesting to study in depth some of the proteins sets identified by the enrichment analysis; among which, PARP1, LIMCH1 and MAPK12 emerge as good candidates.

Figure 4. Integrative model summarizing the main study findings.

Figure 4

Abbreviations: LIMCH1, LIM and calponin homology domains‐containing protein 1; MAPK12, mitogen‐activated protein kinase 12; PARP1, poly (ADP‐ribose) polymerase 1; TIGD4, tigger transposable element derived 4.

Additional information

Competing interests

All the authors declare they have no conflict of interesting.

Author contributions

The experiments were performed in the Centre of Energy, Environment and Technical Research, CIEMAT (mouse genotyping, housing and training); and Centro Nacional de Investigaciones (Cardiovasculares): proteomics. C.F.L.: conception and design of the work, acquisition, analysis and interpretation of data for the work, and drafting the work; A.S.L. and J.L.Z.: design of the work, analysis and interpretation of data for the work, and drafting the work; F.L., J.A., M.A.M., A.L.A., T.P., B.G.B. and J.V.: interpretation of data for the work and revising the work critically for important intellectual content; G.N.G., J.D.B., R.C. and A.G.M.: acquisition of data for the work and revising the work critically for important intellectual content; C.B.: analysis and interpretation of data for the work and revising the work critically for important intellectual content; J.A.L.: analysis and interpretation of data for the work and revising the work critically for important intellectual content; A.L.: conception and design of the work, analysis and interpretation of data for the work, drafting the work. All authors qualify for authorship, approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding

The CNIC is supported by the Ministry of Economy, Industry and Competitiveness (MEIC) and the Pro CNIC Foundation, and is a Severo Ochoa Centre of Excellence (SEV‐2015‐0505). This study was funded by grants from Fondo de Investigaciones Sanitarias (PI15/01756, PI15/00558, PI12/00914, and PI14/00903), cofinanced by FEDER. G.N.G. is supported by a Miguel Servet research contract (ISCIII CD14/00032 and FEDER) and C.F.L. by a Sara Borrell post doc contract (CD14/00005). Miguel A. Martín is supported by Fondo de Investigaciones Sanitarias (FIS 15/00432). Tomâs Pinós is supported by Fondo se Investigaciones Sanitarias (FIS PI16/01492).

Acknowledgements

We thank Dr Kenneth McCreath for his editorial assistance during manuscript preparation. The authors also thank Anaxomic Biotech (Spain) for bioinformatic support in the proteomic data analysis.

Tables A1A9.

Table A1.

Molecular effectors of skeletal muscle adaptations to endurance exercise training determined through the review of specialized scientific literature

MOTIVE ID Effector protein (name) Effector protein (short name)
Adaptive muscle growth 40S ribosomal protein S6 RPS6 (rpS6)
E3 ubiquitin‐protein ligase TRIM63 TRIM63
Elongation factor 2 EEF2
Eukaryotic translation initiation factor 4B IF4B
Eukaryotic translation initiation factor 4E EIF4E (eIF4E )
Eukaryotic translation initiation factor 4E‐binding protein 1 EIF4EBP1 (4EBP1)
Forkhead box protein O3 FOXO3
Growth/differentiation factor 8 MSTN
Mechanistic target of rapamycin mTOR
Peroxisome proliferator‐activated receptor γ coactivator 1‐α PGC‐1α
Phospholipase D1 PLD1
Phospholipase D2 PLD2
Ribosomal protein S6K 1 RPS6KB1 (p70S6K1)
Ribosomal protein S6K 2 RPS6KB2 (p70S6K2)
Angiogenesis Cyclic AMP‐dependent transcription factor ATF‐2 ATF2
Mitogen‐activated protein kinase 12 MAPK12 (p38g)
Myocyte‐specific enhancer factor 2A MEF2A (MEF2)
Nitric oxide synthase, endothelial NOS3
Peroxisome proliferator‐activated receptor γ coactivator 1‐α PGC‐1α
Steroid hormone receptor ERR1 ESRRA (ERRa)
Thrombospondin‐1 TSP‐1
Vascular endothelial growth factor A VEGFA
Glucose and lipid metabolism adaptations α‐Enolase ENO1
β‐Enolase ENO3
Carnitine O‐palmitoyltransferase 1, muscle isoform CPT1B
Fatty acid‐binding protein, heart FABP3 (FABPH)
Glycogen phosphorylase, muscle form PYGM
Glyoxalase I (lactoylglutathione lyase) GLO1
Muscle form hexokinase HK2
Muscle‐type aldolase ALDOA
Platelet glycoprotein 4 FAT/CD36
Pyruvate dehydrogenase E1 component subunit α, somatic form, mitochondrial PDHA1 (PDHa)
Pyruvate dehydrogenase E1 component subunit β, mitochondrial PDHB (PDHb)
Solute carrier family 2, facilitated glucose transporter member 4 SLC2A4 (GLUT4)
Mitochondrial biogenesis and remodelling 5‐Aminolevulinate synthase, non‐specific, mitochondrial ALAS1
5′‐AMP‐activated protein kinase catalytic subunit α‐1 PRKAA1 (AMPKa1)
5′‐AMP‐activated protein kinase catalytic subunit α‐2 PRKAA1 (AMPKa2)
5′‐AMP‐activated protein kinase subunit β‐1 PRKAB1 (AMPKb)
5′‐AMP‐activated protein kinase subunit γ‐1 PRKAG1 (AMPKg)
ATP synthase subunit β, mitochondrial ATP5B
BCL2/adenovirus E1B 19 kDa protein‐interacting protein 3 BNIP3
BCL2/adenovirus E1B 19 kDa protein‐interacting protein 3‐like BNIP3L
Cyclic AMP‐dependent transcription factor 2 ATF2
Cytochrome c oxidase subunit 1 MT‐CO1
Cytochrome c oxidase subunit 2 MT‐CO2
Cytochrome c oxidase subunit 3 MT‐CO3
Cytochrome c oxidase subunit 4 isoform 1, mitochondrial COX4I1
Cytochrome c oxidase subunit 4 isoform 2, mitochondria COX4I2
Cytochrome c oxidase subunit 5A, mitochondrial COX5A
Cytochrome c oxidase subunit 5B, mitochondrial COX5B
Cytochrome c oxidase subunit 6A1, mitochondrial Cox6a1
Cytochrome c oxidase subunit 6A2, mitochondrial Cox6a2
Cytochrome c oxidase subunit 6B1 Cox6b1
Cytochrome c oxidase subunit 6B2 Cox6b2
Cytochrome c oxidase subunit 6C Cox6c
Cytochrome c oxidase subunit 7A‐related protein, mitochondrial Cox7r
Cytochrome c oxidase subunit 7A1, mitochondrial Cox7a1
Cytochrome c oxidase subunit 7A2, mitochondrial Cox7a2
Cytochrome c oxidase subunit 7B, mitochondrial Cox7b
Cytochrome c oxidase subunit 7C, mitochondrial Cox7c
Cytochrome c oxidase subunit 8A, mitochondrial P Cox8a
Cytochrome c oxidase subunit 8C, mitochondrial Cox8c
E3 ubiquitin‐protein ligase parkin PARK2 (PARKIN)
FUN14 domain‐containing protein 1 FUNDC1
Microtubule‐associated proteins 1A/1B light chain 3B MAP1LC3B (LC3)
Mitochondrial fission 1 protein FIS1
Mitofusin‐1 MFN1
Mitofusin‐2 MFN2
Mitogen‐activated protein kinase 11 MAPK11 (p38b)
Mitogen‐activated protein kinase 12 MAPK12 (p38g)
Mitogen‐activated protein kinase 13 MAPK13 (p38d)
Mitogen‐activated protein kinase 14 MAPK14 (p38a)
Myocyte‐specific enhancer factor 2A MEF2A (MEF2 )
NAD‐dependent protein deacetylase sirtuin‐1 SIRT1
Nuclear respiratory factor 1 NRF‐1
Nuclear respiratory factor 2 (GA‐binding protein subunit β‐1) NRF‐2
Peroxisome proliferator‐activated receptor γ coactivator 1‐α PGC‐1α
PTEN‐induced putative kinase protein 1 PINK1
Putative cytochrome c oxidase subunit 7A3, mitochondrial Cox7a3
Serine/threonine‐protein kinase ULK1 ULK1 (ATG1 )
Steroid hormone receptor ERR1 ESRRA (ERRa)
Transcription factor A, mitochondrial TFAM

Table A2.

Summary of training loads in the two exercise groups (McArdle and wild‐type) during the endurance exercise training programme

Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8
Training load variable (5 sessions) (5 sessions) (5 sessions) (5 sessions) (5 sessions) (5 sessions) (5 sessions) (3 sessions)
Intensity (%)* 55 56 61 56 59 65 66 62
(50, 60) (50, 60) (55, 65) (50, 70) (50, 65) (55, 70) (55, 75) (50, 75)
Treadmill inclination (%) 0% 3 9 9 13 14 14 12
(0, 5) (5, 15) (5, 15) (10, 15) (10, 15) (10, 15) (5, 15)
Session duration (min) 32 35 41 40 43 44 45 40
(30, 35) (30, 40) (35, 45) (40, 40) (35, 50) (35, 50) (40, 50) (30, 50)
Distance/session (McArdle, m) 227 264 328 337 341 372 389 396
(207, 255) (219, 305) (292, 364) (324, 362) (280, 386) (349, 412) (261, 462) (219, 455)
Distance/session (wild‐type, m) 303 339 423 432 440 446 463 468
(277, 344) (283, 392) (371, 473) (385, 447) (355, 492) (434, 471) (383, 481) (411, 493)

Data are mean and range (min, max) for the core part of all the sessions within each week. *Determined as percentage of the velocity reached at the end of the maximal performance test performed at the start of the study (abbreviated as V max in the text). Of note, training loads decreased in the two days of the 8th week (Wednesday and Thursday) that preceded the final performance test (Friday).

Table A3.

List of the differentially expressed proteins between the trained and sedentary McArdle mice (n = 123) and the trained and sedentary wild‐type mice (n = 74)

McArdle mice Wild‐type mice
Mouse UniProt ID Human Uniprot ID Gene name Mouse UniProt ID Human Uniprot ID Gene name
O08710 P01266 TG P28028 P15056 BRAF
O08529 P17655 CAPN2 Q9QZK2 O75815 BCAR3
F6TQW2 B1ATL6 P45985 MAP2K4
Q8VCP8 Q9Y3D8 AK6 Q99LH9 Q7L8J4 SH3BP5L
Q5HZY7 O75348 ATP6V1G1 E0CXQ2 P0CG20 PRR35
Q9Z0P5 Q6IBS0 TWF2 Q3UK27 Q13564 NAE1
Q5SSW2 Q14997 PSME4 Q8BFZ3 Q562R1 ACTBL2
Q9DC11 Q6UX71 PLXDC2 Q9D404 Q9NWU1 OXSM
Q9JHU4 Q14204 DYNC1H1 O09167 P46778 RPL21
Q8CHH9 Q92599 SEPT8 Q920Q6 Q96DH6 MSI2
Q5RKZ7 Q9NZB8 MOCS1 P47802 Q13505 MTX1
Q545F5 P56381 ATP5E Q54AE3 P16520 GNB3
P48774 P21266 GSTM3 P59279 Q8WUD1 RAB2B
P70670 E9PAV3 NACA Q9WU62 Q9NQS7 INCENP
Q9Z0 × 1 O95831 AIFM1 P62880 P62879 GNB2
Q99LP6 Q9HAV7 GRPEL1 O08638 P35749 MYH11
D3YUB6 Q5XKL5 BTBD8 Q5M8R8 P05388 RPLP0
O08663 P50579 METAP2 Q9ET01 P06737 PYGL
Q61838 P20742 PZP Q8BUZ3 Q8IY51 TIGD4
Q8C5W0 Q96JQ2 CLMN Q8VHS6 Q8WXK1 ASB15
P01864 A2BFF7 Q13409 DYNC1I2
P01887 P61769 B2M Q99K23 Q9NUQ7 UFSP2
Q3UX10 A6NHL2 TUBAL3 Q6ZQ58 Q6PKG0 LARP1
A0A0A6YW72 Q6V1P9 DCHS2 Q80 × 76
P08121 P02461 COL3A1 Q8BGF0 O00534 VWA5A
O88196 P53804 TTC3 O35206 P39059 COL15A1
P01837 P01834 IGKC P21845 Q15661 TPSAB1
P97371 Q06323 PSME1 Q5XPI3 Q5XPI4 RNF123
Q4VAA2 Q9UKY7 CDV3 Q62348 Q15631 TSN
Q14C59 Q86T26 TMPRSS11B Q9D2M8 Q15819 UBE2V2
Q921I1 P02787 TF E9Q740 O76094 SRP72
Q9R1P0 P25789 PSMA4 Q9CQ89 O60888 CUTA
P05213 P68363 TUBA1B E9PYH6 O15047 SETD1A
P84089 P84090 ERH Q01815 Q13936 CACNA1C
Q3U1N0 P31146 CORO1A Q8BL65 Q6H8Q1 ABLIM2
Q8R0Y8 Q86VD7 SLC25A42 P62862 P35544 FAU
Q5M9K7 P46783 RPS10 Q9D7 × 8 O75223 GGCT
Q9CQH7 Q96K17 BTF3L4 P28650 Q8N142 ADSSL1
Q8R404 Q5XKP0 MIC13 G3 × 9Q1 Q13683 ITGA7
O35857 O43615 TIMM44 P97822 Q9BTT0 ANP32E
P01867 A6H6K1 Q9BXN1 ASPN
Q9R0P9 P09936 UCHL1 P11103 P09874 PARP1
Q4VAE3 Q6PI78 TMEM65 Q60718 Q99965 ADAM2
Q6P549 O15357 INPPL1 P10852 P08195 SLC3A2
F6ZAP6 Q0VBD0 P26012 ITGB8
P62984 P62987 UBA52 P62141 P62140 PPP1CB
O09174 Q9UHK6 AMACR P29341 P11940 PABPC1
E9PYB0 Q8IVF2 AHNAK2 Q8C4G9 Q86SQ6 ADGRA1
Q811B1 Q86Y38 XYLT1 Q8C0K5 P16260 SLC25A16
Q80ZW2 Q8WUY1 THEM6 Q3UH68 Q9UPQ0 LIMCH1
Q9D0F3 P49257 LMAN1 Q69ZX8 O94929 ABLIM3
E9Q616 Q09666 AHNAK P97313 P78527 PRKDC
Q9WUU7 Q9UBR2 CTSZ P31786 P07108 DBI
P09103 P07237 P4HB Q01339 P02749 APOH
P16015 P07451 CA3 Q8VED9 Q3ZCW2 LGALSL
O35593 O00487 PSMD14 Q6R0H7 O95467 GNAS
Q542A1 Q9UHQ4 BCAP29 A2AIM4 P07951 TPM2
Q9EQZ7 Q9UQ26 RIMS2 Q9CXJ4 Q9NUT2 ABCB8
Q9Z2C5 Q13496 MTM1 Q8C181 Q5VZF2 MBNL2
Q8R092 Q9BWL3 C1orf43 Q6ZWU9 P42677 RPS27
Q99J47 Q6IAN0 DHRS7B Q9EPM5 Q9H7C4 SYNC
Q546G4 P02768 ALB P70268 Q16512 PKN1
Q80ZS3 Q9BYN8 MRPS26 Q6IRU7 Q5JTW2 CEP78
P61222 P61221 ABCE1 Q8CHG3 Q8IWJ2 GCC2
Q8CI51 Q96HC4 PDLIM5 Q32NZ6 Q6UXY8 TMC5
A2AE45 Q1XH17 Q6ZMU5 TRIM72
Q9D1M0 P55735 SEC13 Q9Z247 O95302 FKBP9
Q99NB1 Q9NUB1 ACSS1 Q62205 Q15858 SCN9A
Q8BUZ3 Q8IY51 TIGD4 Q8BG95 O60237 PPP1R12B
Q62087 Q15166 PON3 B0QZF7 Q8NCQ7 PROCA1
O88492 Q96Q06 PLIN4 Q8BYH7 Q9HA65 TBC1D17
O55222 Q13418 ILK P11627 P32004 L1CAM
Q3V1H3 Q6MZM0 HEPHL1 O70624 Q99972 MYOC
Q3U4U6 P49368 CCT3 E9QB02 P56192 MARS
Q9JIY5 O43464 HTRA2
P06728 P06727 APOA4
Q544H9 Q96T49 PPP1R16B
P53986 P53985 SLC16A1
A3KGG4 A7MBM2 DISP2
Q61207 P07602 PSAP
Q9JKF7 Q9NYK5 MRPL39
P06330
Q8R2Q4 Q969S9 GFM2
Q9JK42 Q15119 PDK2
Q9CR61 P17568 NDUFB7
Q8CG76 O43488 AKR7A2
Q6PB66 P42704 LRPPRC
P50136 P12694 BCKDHA
O08911 P53778 MAPK12
Q1RLL3 Q8IYJ1 CPNE9
Q8C2K5 Q86YV0 RASAL3
Q80YR9 Q8IXT5 RBM12B
Q4FJQ6 P35237 SERPINB6
Q61001 O15230 LAMA5
Q61187 Q99816 TSG101
Q8K3C3 Q8WZA0 LZIC
P06797 O60911 CTSV
A2AAJ9 Q5VST9 OBSCN
Q3UZA1 Q6JBY9 RCSD1
Q99N13 Q9UKV0 HDAC9
Q8BGK2 Q8NDY3 ADPRHL1
P67778 P35232 PHB
P17047 P13473 LAMP2
D3YX79
Q8CII2 O75794 CDC123
E9PV24 P02671 FGA
P17427 O94973 AP2A2
Q99L88 Q13884 SNTB1
P11103 P09874 PARP1
Q9JHL1 Q15599 SLC9A3R2
Q3U2W2 Q9BQG0 MYBBP1A
Q9WV96 Q9Y5J6 TIMM10B
Q66JT0 P0C1S8 WEE2
A2AKU9 P36542 ATP5C1
A2AP31 O95139 NDUFB6
P33173 Q12756 KIF1A
Q921I2 Q8TBB5 KLHDC4
Q8BTS4 Q7Z3B4 NUP54
D3YU22 Q9UPQ0 LIMCH1
Q61233 P13796 LCP1
P22599 P01009 SERPINA1
Q99MR8 Q96RQ3 MCCC1
Q00623 P02647 APOA1

Table A4.

Number of proteins reported for each artificial neuronal network (ANN) category in relation to skeletal muscle adaptations to endurance exercise training in McArdle and wild‐type mice; information is given for proteins individually (‘individual’), in combination (‘combined’) and both (‘total’)

McArdle Wild‐type
ANN category Individual % Combined % Total % Individual % Combined % Total % Common proteins
Strong (P < 0.05) 4 4% 135 2% 139 2% 0 0% 1 0% 1 0% 0
Medium–strong (P = 0.05–0.25) 29 25% 1900 34% 1 929 33% 16 22% 718 32% 734 31% 1
Weak (P > 0.25) 78 67% 3 636 64% 3 714 64% 52 71% 1 559 68% 1 611 69% 2
Not assessed 5 4% 0 0% 5 0% 5 7% 0 0% 5 0% 0
Total 116 100% 5 671 100% 5 787 100% 73 100% 2 278 100% 2 351 100% 3

Table A5.

Summary of all the enriched protein sets (the corresponding database is also indicated)

Source McArdle mice Wild‐type mice
BED 7 0
BED Motives 9 5
BED Pathways 5 3
GO Function 7 3
GO Location 35 1
GO Process 55 2
PharmGKB 2 1
TRRUST 1 0
KEGG 0 13
SMPDB 0 51
Total 121 79

Abbreviations: BED, Biological Effectors Database; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PharmGKB, Pharmacogenomics Knowledgebase; SMPDB, Small Molecule Pathway Database; TRRUST, Transcriptional Regulatory Relationships Unraveled by Sentence‐based Text‐mining database.

Table A6.

Enriched protein sets related to mitochondrial function in McArdle mice

Source Set name
BED pathways Oxidative phosphorylation (OXPHOS)
GO function ID Proton‐transporting ATP synthase activity, rotational mechanism
GO location Mitochondrial crista junction
GO location Mitochondrial inner membrane
GO location Mitochondrial intermembrane space
GO location Mitochondrial matrix
GO location Mitochondrial proton‐transporting ATP synthase complex
GO location Mitochondrial proton‐transporting ATP synthase complex, catalytic core F(1)
GO location Mitochondrion
GO process Mitochondrion organisation
GO process Protein targeting to mitochondrion
GO process Respiratory electron transport chain

Abbreviations: BED, Biological Effectors Database; GO, Gene Ontology;

Table A7.

Enriched protein sets related to muscle structure and growth

Source Set name
GO location Costamere
GO location Cytoskeleton
GO location Focal adhesion
GO location Membrane
GO location Actin filament
GO process Cell‐matrix adhesion
GO process Integrin‐mediated signalling pathway
GO process Positive regulation of Rho protein signal transduction
GO process Regulation of actin cytoskeleton organization
GO process Mitotic cell cycle
GO process Positive regulation of ubiquitin‐protein ligase activity involved in regulation of mitotic cell cycle transition
GO process Regulation of ubiquitin‐protein ligase activity involved in mitotic cell cycle

Abbreviations: GO, Gene Ontology.

Table A8.

Summary of the enriched protein sets related to increase in muscle size and function, and neuromodulation

SOURCE SET_NAME
KEGG 04510 _Focal adhesion
KEGG 04810 _Regulation of actin cytoskeleton
KEGG 04151 _PI3K‐Akt signalling pathway
BED pathways Gastrointestinal smooth muscle sustained contraction
BED pathways Smooth muscle relaxation
BED pathways Vascular smooth muscle contraction
KEGG 04270 _Vascular smooth muscle contraction
GO function poly(U) RNA binding
GO function Translation activator activity
GO process Small GTPase mediated signal transduction
GO process Translational initiation
KEGG 03015 _mRNA surveillance pathway
BED motives Nervous impluse generation deffect
KEGG 04713 _Circadian entrainment
KEGG 04151 _PI3K‐Akt signalling pathway
KEGG 04720 _Long‐term potentiation
KEGG 04726 _Serotonergic synapse
KEGG 04727 _GABAergic synapse
KEGG 04728_Dopaminergic synapse

Abbreviations: BED, Biological Effectors Database; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

Table A9.

Summary of the enriched protein set related to catecholamine modulation within wild‐type (wt/wt) mice; set sources are also indicated

Source Set name Source Set name
PHARMKB [PA2024] Beta‐agonist/beta‐blocker pathway, pharmacodynamics SMPDB [SMP00367] Carvedilol action pathway
SMPDB [SMP00296] Acebutolol action pathway SMPDB [SMP00368] Labetalol action pathway
SMPDB [SMP00297] Alprenolol action pathway SMPDB [SMP00375] Verapamil action pathway
SMPDB [SMP00298] Atenolol action pathway SMPDB [SMP00376] Amlodipine action pathway
SMPDB [SMP00299] Betaxolol action pathway SMPDB [SMP00377] Felodipine action pathway
SMPDB [SMP00300] Bisoprolol action pathway SMPDB [SMP00378] Isradipine action pathway
SMPDB [SMP00301] Esmolol action pathway SMPDB [SMP00379] Nifedipine action pathway
SMPDB [SMP00302] Metoprolol action pathway SMPDB [SMP00380] Nimodipine action pathway
SMPDB [SMP00303] Nadolol action pathway SMPDB [SMP00381] Nisoldipine action pathway
SMPDB [SMP00304] Oxprenolol action pathway SMPDB [SMP00382] Nitrendipine action pathway
SMPDB [SMP00305] Penbutolol action pathway SMPDB [SMP00588] Muscle/heart contraction
SMPDB [SMP00306] Pindolol action pathway SMPDB [SMP00619] Felodipine metabolism pathway
SMPDB [SMP00307] Propranolol action pathway SMPDB [SMP00657] Bopindolol action pathway
SMPDB [SMP00320] Intracellular signalling through adenosine receptor A2a and adenosine SMPDB [SMP00658] Carteolol action pathway
SMPDB [SMP00321] Intracellular signalling through adenosine receptor A2b and adenosine SMPDB [SMP00659] Timolol action pathway
SMPDB [SMP00323] Quinidine action pathway SMPDB [SMP00660] Sotalol action pathway
SMPDB [SMP00324] Procainamide (antiarrhythmic) action pathway SMPDB [SMP00661] Epinephrine action pathway
SMPDB [SMP00325] Disopyramide action pathway SMPDB [SMP00662] Dobutamine action pathway
SMPDB [SMP00326] Fosphenytoin (antiarrhythmic) action pathway SMPDB [SMP00663] Isoprenaline action pathway
SMPDB [SMP00328] Lidocaine (antiarrhythmic) action SMPDB [SMP00664] Arbutamine action pathway
SMPDB [SMP00329] Mexiletine action pathway SMPDB [SMP00665] Amiodarone action pathway
SMPDB [SMP00330] Tocainide action pathway SMPDB [SMP00666] Levobunolol action pathway
SMPDB [SMP00331] Flecainide action pathway SMPDB [SMP00667] Metipranolol action pathway
SMPDB [SMP00332] Ibutilide action pathway SMPDB [SMP00668] Bevantolol action pathway
SMPDB [SMP00359] Diltiazem action pathway SMPDB [SMP00669] Practolol action pathway
SMPDB [SMP00366] Nebivolol action pathway SMPDB [SMP00670] Bupranolol action pathway

Edited by: Scott Powers & Bruno Grassi

C. Fiuza‐Luces and A. Santos‐Lozano contributed equally to this work.

J. L. Zugaza and A. Lucia share senior authorship.

References

  1. Altschul SF, Gish W, Miller W, Myers EW & Lipman DJ (1990). Basic local alignment search tool. J Mol Biol 215, 403–410. [DOI] [PubMed] [Google Scholar]
  2. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH & Drucker DJ (2009). The glucagon‐like peptide‐1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150, 1155–1164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartlett JD, Hawley JA & Morton JP (2015). Carbohydrate availability and exercise training adaptation: too much of a good thing? Eur J Sport Sci 15, 3–12. [DOI] [PubMed] [Google Scholar]
  4. Bassel‐Duby R & Olson EN (2006). Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem 75, 19–37. [DOI] [PubMed] [Google Scholar]
  5. Berenbaum MC (1989). What is synergy? Pharmacol Rev 41, 93–141. [PubMed] [Google Scholar]
  6. Bergstrom J, Hermansen L, Hultman E & Saltin B (1967). Diet, muscle glycogen and physical performance. Acta Physiol Scand 71, 140–150. [DOI] [PubMed] [Google Scholar]
  7. Blake JA, Eppig JT, Kadin JA, Richardson JE, Smith CL, Bult CJ & the Mouse Genome Database Group (2017). Mouse Genome Database (MGD) – 2017: community knowledge resource for the laboratory mouse. Nucleic Acids Res 45, D723–D729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bonzon‐Kulichenko E, Garcia‐Marques F, Trevisan‐Herraz M & Vazquez J (2015). Revisiting peptide identification by high‐accuracy mass spectrometry: problems associated with the use of narrow mass precursor windows. J Proteome Res 14, 700–710. [DOI] [PubMed] [Google Scholar]
  9. Brull A, de Luna N, Blanco‐Grau A, Lucia A, Martin MA, Arenas J, Marti R, Andreu AL & Pinos T (2015). Phenotype consequences of myophosphorylase dysfunction: insights from the McArdle mouse model. J Physiol 593, 2693–2706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cardona M, Lopez JA, Serafin A, Rongvaux A, Inserte J, Garcia‐Dorado D, Flavell R, Llovera M, Canas X, Vazquez J & Sanchis D (2015). Executioner caspase‐3 and 7 deficiency reduces myocyte number in the developing mouse heart. PLoS One 10, e0131411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cuenda A & Rousseau S (2007). p38 MAP‐kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773, 1358–1375. [DOI] [PubMed] [Google Scholar]
  12. Favier FB, Benoit H & Freyssenet D (2008). Cellular and molecular events controlling skeletal muscle mass in response to altered use. Pflugers Arch 456, 587–600. [DOI] [PubMed] [Google Scholar]
  13. Fiuza‐Luces C, Nogales‐Gadea G, García‐Consuegra I, Pareja‐Galeano H, Rufián‐Vázquez L, Pérez LM, Andreu AL, Arenas J, Martín MA, Pinós T, Lucia A & Morán M (2016). Muscle signaling in exercise intolerance: insights from the McArdle mouse model. Med Sci Sports Exerc 48, 1448–1458. [DOI] [PubMed] [Google Scholar]
  14. Fiuza‐Luces C, Soares‐Miranda L, Gonzalez‐Murillo A, Palacio JM, Colmenero I, Casco F, Melen GJ, Delmiro A, Moran M, Ramirez M & Lucia A (2013). Exercise benefits in chronic graft versus host disease: a murine model study. Med Sci Sports Exerc 45, 1703–1711. [DOI] [PubMed] [Google Scholar]
  15. Frolkis A, Knox C, Lim E, Jewison T, Law V, Hau DD, Liu P, Gautam B, Ly S, Guo AC, Xia J, Liang Y, Shrivastava S & Wishart DS (2010). SMPDB: The Small Molecule Pathway Database. Nucleic Acids Res 38, D480–D487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Frontera WR & Ochala J (2015). Skeletal muscle: a brief review of structure and function. Calcif Tissue Int 96, 183–195. [DOI] [PubMed] [Google Scholar]
  17. Garcia‐Marques F, Trevisan‐Herraz M, Martinez‐Martinez S, Camafeita E, Jorge I, Lopez JA, Mendez‐Barbero N, Mendez‐Ferrer S, Del Pozo MA, Ibanez B, Andres V, Sanchez‐Madrid F, Redondo JM, Bonzon‐Kulichenko E & Vazquez J (2016). A novel systems‐biology algorithm for the analysis of coordinated protein responses using quantitative proteomics. Mol Cell Proteomics 15, 1740–1760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Grundy D (2015). Principles and standards for reporting animal experiments in The Journal of Physiology and Experimental Physiology . J Physiol 593, 2547–2549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ha HC & Snyder SH (1999). Poly(ADP‐ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96, 13978–13982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Haller RG, Wyrick P, Taivassalo T & Vissing J (2006). Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 59, 922–928. [DOI] [PubMed] [Google Scholar]
  21. Han H, Shim H, Shin D, Shim JE, Ko Y, Shin J, Kim H, Cho A, Kim E, Lee T, Kim H, Kim K, Yang S, Bae D, Yun A, Kim S, Kim CY, Cho HJ, Kang B, Shin S & Lee I (2015). TRRUST: a reference database of human transcriptional regulatory interactions. Sci Rep 5, 11432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Herrando‐Grabulosa M, Mulet R, Pujol A, Mas JM, Navarro X, Aloy P, Coma M & Casas C (2016). Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systems. PLoS One 11, e0147626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ho RC, Alcazar O, Fujii N, Hirshman MF & Goodyear LJ (2004). p38gamma MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle. Am J Physiol Regul Integr Comp Physiol 286, R342–R349. [DOI] [PubMed] [Google Scholar]
  24. Hoydal MA, Wisloff U, Kemi OJ & Ellingsen O (2007). Running speed and maximal oxygen uptake in rats and mice: practical implications for exercise training. Eur J Cardiovasc Prev Rehabil 14, 753–760. [DOI] [PubMed] [Google Scholar]
  25. Iborra‐Egea O, Galvez‐Monton C, Roura S, Perea‐Gil I, Prat‐Vidal C, Soler‐Botija C & Bayes‐Genis A (2017). Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl 3, 12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Isern J, Martin‐Antonio B, Ghazanfari R, Martin AM, Lopez JA, del Toro R, Sanchez‐Aguilera A, Arranz L, Martin‐Perez D, Suarez‐Lledo M, Marin P, Van Pel M, Fibbe WE, Vazquez J, Scheding S, Urbano‐Ispizua A & Mendez‐Ferrer S (2013). Self‐renewing human bone marrow mesenspheres promote hematopoietic stem cell expansion. Cell Rep 3, 1714–1724. [DOI] [PubMed] [Google Scholar]
  27. Jungmichel S, Rosenthal F, Altmeyer M, Lukas J, Hottiger MO & Nielsen ML (2013). Proteome‐wide identification of poly(ADP‐ribosyl)ation targets in different genotoxic stress responses. Mol Cell 52, 272–285. [DOI] [PubMed] [Google Scholar]
  28. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M & Tanabe M (2014). Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 42, D199–D205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Koulmann N & Bigard AX (2006). Interaction between signalling pathways involved in skeletal muscle responses to endurance exercise. Pflugers Arch 452, 125–139. [DOI] [PubMed] [Google Scholar]
  30. Krag TO, Pinos T, Nielsen TL, Brull A, Andreu AL & Vissing J (2016a). Differential muscle involvement in mice and humans affected by McArdle disease. J Neuropathol Exp Neurol 75, 441–454. [DOI] [PubMed] [Google Scholar]
  31. Krag TO, Pinós T, Nielsen TL, Duran J, García‐Rocha M, Andreu AL & Vissing J (2016b). Differential glucose metabolism in mice and humans affected by McArdle disease. Am J Physiol Regul Integr Comp Physiol 311, R307–R314. [DOI] [PubMed] [Google Scholar]
  32. Lane SC, Camera DM, Lassiter DG, Areta JL, Bird SR, Yeo WK, Jeacocke NA, Krook A, Zierath JR, Burke LM & Hawley JA (2015). Effects of sleeping with reduced carbohydrate availability on acute training responses. J Appl Physiol (1985) 119, 643–655. [DOI] [PubMed] [Google Scholar]
  33. Lin YH, Zhen YY, Chien KY, Lee IC, Lin WC, Chen MY & Pai LM (2017). LIMCH1 regulates nonmuscle myosin‐II activity and suppresses cell migration. Mol Biol Cell 28, 1054–1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lucia A, Nogales‐Gadea G, Perez M, Martin MA, Andreu AL & Arenas J (2008). McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol 4, 568–577. [DOI] [PubMed] [Google Scholar]
  35. Lucia A, Ruiz JR, Santalla A, Nogales‐Gadea G, Rubio JC, Garcia‐Consuegra I, Cabello A, Perez M, Teijeira S, Vieitez I, Navarro C, Arenas J, Martin MA & Andreu AL (2012). Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry 83, 322–328. [DOI] [PubMed] [Google Scholar]
  36. Martinez‐Bartolome S, Navarro P, Martin‐Maroto F, Lopez‐Ferrer D, Ramos‐Fernandez A, Villar M, Garcia‐Ruiz JP & Vazquez J (2008). Properties of average score distributions of SEQUEST: the probability ratio method. Mol Cell Proteomics 7, 1135–1145. [DOI] [PubMed] [Google Scholar]
  37. Mate‐Munoz JL, Moran M, Perez M, Chamorro‐Vina C, Gomez‐Gallego F, Santiago C, Chicharro L, Foster C, Nogales‐Gadea G, Rubio JC, Andreu AL, Martin MA, Arenas J & Lucia A (2007). Favorable responses to acute and chronic exercise in McArdle patients. Clin J Sport Med 17, 297–303. [DOI] [PubMed] [Google Scholar]
  38. Navarro P, Trevisan‐Herraz M, Bonzon‐Kulichenko E, Nunez E, Martinez‐Acedo P, Perez‐Hernandez D, Jorge I, Mesa R, Calvo E, Carrascal M, Hernaez ML, Garcia F, Barcena JA, Ashman K, Abian J, Gil C, Redondo JM & Vazquez J (2014). General statistical framework for quantitative proteomics by stable isotope labeling. J Proteome Res 13, 1234–1247. [DOI] [PubMed] [Google Scholar]
  39. Navarro P & Vazquez J (2009). A refined method to calculate false discovery rates for peptide identification using decoy databases. J Proteome Res 8, 1792–1796. [DOI] [PubMed] [Google Scholar]
  40. Nogales‐Gadea G, Pinos T, Lucia A, Arenas J, Camara Y, Brull A, de Luna N, Martin MA, Garcia‐Arumi E, Marti R & Andreu AL (2012). Knock‐in mice for the R50X mutation in the PYGM gene present with McArdle disease. Brain 135, 2048–2057. [DOI] [PubMed] [Google Scholar]
  41. Pache RA, Zanzoni A, Naval J, Mas JM & Aloy P (2008). Towards a molecular characterisation of pathological pathways. FEBS Lett 582, 1259–1265. [DOI] [PubMed] [Google Scholar]
  42. Pernow B & Saltin B (1971). Availability of substrates and capacity for prolonged heavy exercise in man. J Appl Physiol 31, 416–422. [DOI] [PubMed] [Google Scholar]
  43. Rivals I, Personnaz L, Taing L & Potier MC (2007). Enrichment or depletion of a GO category within a class of genes: which test? Bioinformatics 23, 401–407. [DOI] [PubMed] [Google Scholar]
  44. Russell AP ( 2010). Molecular regulation of skeletal muscle mass. Clin Exp Pharmacol Physiol 37, 378–384. [DOI] [PubMed] [Google Scholar]
  45. Santalla A, Nogales‐Gadea G, Ortenblad N, Brull A, de Luna N, Pinos T & Lucia A (2014). McArdle disease: a unique study model in sports medicine. Sports Med 44, 1531–1544. [DOI] [PubMed] [Google Scholar]
  46. Sonnhammer EL & Ostlund G (2015). InParanoid 8: orthology analysis between 273 proteomes, mostly eukaryotic. Nucleic Acids Res 43, D234–D239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. The UniProt Consortium (2017). UniProt: the universal protein knowledgebase. Nucleic Acids Res 45, D158–D169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Turk WR, Heller SL, Norris BJ & Nemeth PM (1990). Increased muscular β‐hydroxyacyl CoA dehydrogenase with McArdle's disease. Muscle Nerve 13, 607–612. [DOI] [PubMed] [Google Scholar]
  49. Vissing J & Haller RG (2003). The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 349, 2503–2509. [DOI] [PubMed] [Google Scholar]
  50. Webster CC, Noakes TD, Chacko SK, Swart J, Kohn TA & Smith JA (2016). Gluconeogenesis during endurance exercise in cyclists habituated to a long‐term low carbohydrate high‐fat diet. J Physiol 594, 4389–4405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Whirl‐Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB & Klein TE (2012). Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92, 414–417. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Physiology are provided here courtesy of The Physiological Society

RESOURCES